Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 04:31 am EDT
Share
Anhui Anke Biotechnology (Group) Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 533.36 million compared to CNY 484.83 million a year ago. Revenue was CNY 533.36 million compared to CNY 484.83 million a year ago. Net income was CNY 172.9 million compared to CNY 125.58 million a year ago. Basic earnings per share from continuing operations was CNY 0.1055 compared to CNY 0.0767 a year ago. Diluted earnings per share from continuing operations was CNY 0.1055 compared to CNY 0.0767 a year ago.
Anhui Anke Biotechnology Group Co Ltd is a China-based company mainly engaged in the research and development, production and sales of genetic engineering drugs and biological detection reagents. The Company's products mainly include biological products, modern Chinese patent medicines, chemical synthetic drugs, and peptide drugs. The Company's subsidiary business covers the research and development, production and sales of modern Chinese patent medicines, chemical synthetic drugs, peptide drugs, forensic DNA testing, cell drugs and other products.